SL PHARM(002038)2024-04-23 11:24Financial Performance - The net profit attributable to shareholders decreased by 65.27% compared to the same period last year, primarily due to a significant reduction in investment income and fair value changes, with fair value changes decreasing by 143% year-on-year[23] - The company's operating revenue for the current period is ¥245,116,238.48, a decrease of 17.35% compared to the same period last year, which was ¥296,576,777.05[29] - The net profit attributable to shareholders of the listed company is ¥70,134,618.06, reflecting a significant decline of 65.27% from ¥201,929,706.82 in the previous year[29] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 6.62% to ¥101,583,927.04 from ¥95,274,495.59 year-on-year[29] - The basic and diluted earnings per share both decreased to ¥0.07, down 65.00% from ¥0.20 in the same period last year[29] - The weighted average return on equity fell to 1.20%, down 2.43% from 3.63% in the previous year[29] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥6,311,959,999.77, an increase from ¥6,277,761,845.44 at the beginning of the period[12] - The total liabilities decreased from ¥467,724,343.08 to ¥432,246,690.92, reflecting a reduction in both current and non-current liabilities[12] - The total current assets increased from ¥2,639,981,026.24 to ¥2,675,312,708.26, driven by an increase in inventory and accounts receivable[10] - The long-term equity investments increased slightly from ¥905,919,506.61 to ¥911,366,506.82[11] - The company’s other non-current assets totaled ¥800,646,130.83, up from ¥792,361,780.21[11] - The total equity attributable to shareholders increased from ¥5,800,616,100.16 to ¥5,870,750,718.22[12] - The equity attributable to shareholders of the listed company rose by 1.21% to ¥5,870,750,718.22 compared to ¥5,800,616,100.16 at the end of the previous year[29] Cash Flow - Cash and cash equivalents at the end of the period were ¥643,139,595.37, down from ¥683,831,097.67 at the beginning of the period[10] - The net cash flow from operating activities decreased by 5.17% to ¥106,747,075.24 from ¥112,566,260.06 in the previous year[29] - The total cash inflow from operating activities was CNY 273,602,084.46, a decrease of 13.7% compared to CNY 316,981,003.07 in the previous period[53] - The net cash outflow from operating activities was CNY 166,855,009.22, compared to CNY 204,414,743.01 in the previous period, indicating improved cash management[53] - The cash received from sales of goods and services was CNY 270,755,128.82, down from CNY 313,916,926.02 in the previous period, reflecting a decline in sales[53] - The cash paid to employees increased to CNY 38,363,060.64 from CNY 33,357,923.54, representing a rise of 15%[53] - The cash paid for other operating activities decreased significantly to CNY 16,130,926.18 from CNY 66,885,615.10, showing improved cost control[53] - The company reported a net cash inflow from operating activities of CNY 106,747,075.24, slightly lower than CNY 112,566,260.06 in the previous period[53] Investment Activities - The company reported an investment income of ¥7,460,885.69, a decrease from ¥20,472,754.57 in the previous year[36] - The cash inflow from investment activities was CNY 3,300,000.00, down from CNY 9,430,244.89 in the previous period, indicating reduced investment returns[53] - The company invested 26,093,699.08, indicating continued capital expenditures[54] Shareholder Information - The total number of common shareholders at the end of the reporting period was 69,014, reflecting a stable shareholder base[46] - The largest shareholder, Xu Mingbo, holds 22.62% of the shares, indicating significant insider ownership[46]